Semaglutide
The benchmark GLP-1 peptide that reshaped diabetes and obesity medicine by slowing digestion and turning down hunger signals in the brain.
Semaglutide Biological Classification
The benchmark GLP-1 peptide that reshaped diabetes and obesity medicine by slowing digestion and turning down hunger signals in the brain.
Gastric Motility Slowing
Delays the rate at which food leaves the stomach, prolonging feelings of fullness after meals.
Hypothalamic Appetite Suppression
Crosses into the brain's appetite regulation centers, dampening hunger signals and reducing 'food noise'.
Glucose-Dependent Insulin Release
Prompts the pancreas to secrete insulin only when blood sugar is elevated, virtually eliminating hypoglycemic crashes.
What is Semaglutide?
Semaglutide is a modified, long-acting synthetic analogue of human Glucagon-Like Peptide-1 (GLP-1). It is engineered with a fatty acid side-chain that binds tightly to albumin in the bloodstream, slowing its clearance so it can be administered once weekly instead of multiple times a day.
Why are people interested in it?
Semaglutide transformed modern metabolic medicine. Commercialized as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management), it demonstrated that medical therapy could safely achieve 15% average weight reduction along with major cardiovascular risk reductions.
Primary Research Categories
- Incretin analogues
- Approved drug substances
How does it work in the body?
Semaglutide mimics the gut hormone GLP-1, which the intestines naturally release after eating to regulate digestion, blood sugar, and satiety.
Biological Pathway Overview
Semaglutide Receptor & Target Interactions
This compound is evaluated in scientific research for its interactions with target cellular receptors and signaling cascades. Consult the evidence section below for specific peer-reviewed papers.
Gastric Motility Slowing
Delays the rate at which food leaves the stomach, prolonging feelings of fullness after meals.
Hypothalamic Appetite Suppression
Crosses into the brain's appetite regulation centers, dampening hunger signals and reducing 'food noise'.
Glucose-Dependent Insulin Release
Prompts the pancreas to secrete insulin only when blood sugar is elevated, virtually eliminating hypoglycemic crashes.
What has actually been demonstrated in humans?
Semaglutide is backed by one of the largest global clinical trial programs in history (the STEP, SUSTAIN, and SELECT trials) involving tens of thousands of human participants over multiple years.
STEP 1 Trial (Wilding et al., NEJM 2021)
Duration: 68 weeks · Population: 1,961 adults with overweight or obesity without diabetesPublished Finding: Mean body weight change of -14.9% with semaglutide 2.4 mg once weekly compared to -2.4% with placebo. 86% achieved at least 5% weight loss.
SELECT Cardiovascular Trial (Lincoff et al., NEJM 2023)
Duration: Up to 5 years (mean 39.8 months) · Population: 17,604 adults with cardiovascular disease and overweight/obesityPublished Finding: 20% relative reduction in major adverse cardiovascular events (death, nonfatal myocardial infarction, nonfatal stroke).
Pharmaceutical Reality vs. Unregulated Research Chemicals
Approved brand-name products (Wegovy, Ozempic, Rybelsus) are manufactured under strict pharmaceutical GMP guidelines. Non-prescription or 'research chemical' versions marketed online carry serious contamination, inaccurate dosing, and unapproved salt-form risks.
What is still uncertain or unknown?
Long-term real-world persistence is challenging; high discontinuation rates often result in weight regain. Preservation of lean muscle mass during rapid weight loss requires ongoing research and structured resistance training.
Clinical Perspectives & Expert Discussions
Explore all perspectivesWhat identifiable clinicians, researchers, and professional bodies have publicly discussed regarding Semaglutide.
Dr. Peter Attia, M.D.
M.D. (Stanford University School of Medicine); former surgical oncology fellow at National Cancer Institute (NIH); author of Outlive: The Science and Art of Longevity; host of The Drive podcast.
Dr. Attia publicly analyzes the metabolic effects of GLP-1 and multi-agonist incretins, cautioning that rapid scale weight loss often includes 25% to 40% skeletal muscle and lean organ mass loss if progressive heavy resistance training and adequate dietary protein (roughly 1 gram per pound of target body weight) are not strictly prioritized.
Dr. Tyna Moore, N.D., D.C.
Licensed Naturopathic Physician (N.D., National University of Natural Medicine) and Chiropractor (D.C., University of Western States) in Oregon; host of The Dr. Tyna Show.
Dr. Moore discusses an alternative clinical approach advocating for conservative starting doses and slower titration schedules than standard pharmaceutical escalation protocols. She argues that starting with lower amounts allows patients to evaluate GI tolerance, manage autonomic nervous system adaptation, and achieve metabolic anti-inflammatory benefits without triggering rapid muscle catabolism.
The Endocrine Society
Global medical organization representing over 18,000 endocrinologists, researchers, and clinical educators.
Consensus clinical guidelines recommend high-potency incretin receptor agonists (semaglutide, tirzepatide) as foundational adjuncts to lifestyle intervention for adults with obesity or weight-related comorbidities. The guideline emphasizes structured monthly dose escalation, long-term adherence to sustain metabolic benefits, and cautions against abrupt discontinuation, which typically results in weight regain.
Dosing Reference
Open Semaglutide Dosing ReferenceAn approved drug with labelled schedules. Unapproved GLP-1 products are a separate regulatory matter and their contents are not the labelled drug.
Therapept separates official product labels, published clinical study interventions, animal research, clinical references, and community-reported ranges — never blended into one number.
Research at a Glance
Open the full evidence file (4 records)4 records in this file
- CLINICAL TRIAL2
- REGULATORY2
Publication span: 2016–2026
What Has Actually Been Studied
- FDA's concerns about unapproved GLP-1 drugs used for weight loss (FDA drug alerts and statements, 2026) — Regulatory communication.
- Drugs@FDA — Ozempic (NDA 209637), Rybelsus (NDA 213051), Wegovy (NDA 215256) (Drugs@FDA, 2021) — Approved-drug labelling.
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (New England Journal of Medicine, 2021) — Randomised, double-blind, placebo-controlled trial.
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) (New England Journal of Medicine, 2016) — Randomised, double-blind, placebo-controlled cardiovascular trial.
What is Still Unknown
What we know
- Three FDA-approved products exist (Ozempic, Rybelsus, Wegovy), with large Phase 3 programmes (including STEP 1 and SUSTAIN-6) published in NEJM.
- That evidence base is about the approved, labelled products under medical supervision — not about unapproved GLP-1 products.
- FDA has issued separate communications on unapproved GLP-1 products marketed for weight loss.
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
- Nothing in this file characterises unapproved look-alike products. Their composition is a documentation problem for a specific lot.
Combinations and Stacks
- Cagrilintide + Semaglutide
An investigational amylin analogue combined with an approved GLP-1 receptor agonist in a sponsor's Phase 3 programme for weight management — the rare pairing where the combination itself is genuinely under study..
Preparation and Handling
Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.
United States Regulatory Status
FDA-approved drug substance
Application: NDA 209637 (Ozempic), NDA 213051 (Rybelsus), NDA 215256 (Wegovy)
Approved Indication: Marketed in the United States as three approved prescription products: Ozempic and Rybelsus (type 2 diabetes mellitus) and Wegovy (chronic weight management).
- Approved prescription drug substance. Ozempic approved 5 December 2017; Rybelsus 20 September 2019; Wegovy 4 June 2021.
- Not placed in FDA's Category 2 of bulk substances that may present significant safety risks.
- FDA proposed in April 2026 to exclude semaglutide from the 503B bulks list, stating it did not identify sufficient evidence for inclusion.
- FDA has issued separate communications concerning unapproved GLP-1 products marketed for weight loss.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
- Molecular weight
- 4114 g/mol
- Sequence length
- 122 chars
- CAS number
- 910463-68-2
- PubChem CID
- 56843331
- Compound class
- GLP-1 receptor agonist (acylated GLP-1 analogue)
- Sequence
- 31-residue GLP-1 analogue with Aib at position 2 and Lys20 acylated via two AEEA linkers and γ-Glu to octadecanedioic acid
- Molecular formula
- C187H291N45O59
- Molecular weight
- 4114 g/mol
- CAS number
- 910463-68-2
- PubChem CID
- 56843331
Sources
Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built